Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-04
2005-01-04
Spivack, Phyllis (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S267000, C514S274000
Reexamination Certificate
active
06838469
ABSTRACT:
Pharmaceutical compositions that exhibit reduced gastrointestinal side-effects comprising a known active substance having antitumor effects selected from the group consisting of pyrimidine derivatives, or a pharmaceutically acceptable acid addition salt thereof, and O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime, or a pharmaceutically acceptable acid addition salt thereof, are disclosed.
REFERENCES:
patent: 4308399 (1981-12-01), Takacs et al.
patent: 5147879 (1992-09-01), Nagy et al.
patent: 5239077 (1993-08-01), Bertok et al.
patent: 5278309 (1994-01-01), Bertok et al.
patent: 6143741 (2000-11-01), Jednakovits et al.
patent: WO9713504 (1997-04-01), None
Watson S.A. et al, BIODRUGS, (1998), 9/4, (325-335).
Carter et al., Chemotherapy of Cancer, Second Edition, John Wiley & Sons, N.Y., N.Y., pp. 107-108, (Aug. 1981).
Birch & Stewart Kolasch & Birch, LLP
N-Gene Research Laboratories Inc.
Spivack Phyllis
LandOfFree
Pharmaceutical composition that exhibits reduced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition that exhibits reduced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition that exhibits reduced... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3399580